Rock Springs Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-2,306,196
Closed -$41.5M – 162
2020
Q2
$41.5M Buy
2,306,196
+554,296
+32% +$7.71M 1.14% 29
2020
Q1
$12.5M Buy
1,751,900
+851,900
+95% +$10.6M 0.52% 64
2019
Q4
$21.5M Sell
900,000
-150,000
-14% -$4.14M 0.68% 58
2019
Q3
$28.2M Buy
1,050,000
+42,000
+4% +$1.18M 1.12% 27
2019
Q2
$27.3M Buy
1,008,000
+133,000
+15% +$4.17M 0.99% 34
2019
Q1
$30.4M Buy
875,000
+575,000
+192% +$16.6M 1.17% 23
2018
Q4
$5.86M Sell
300,000
-23,800
-7% -$489K 0.28% 91
2018
Q3
$8.62M Hold
323,800
– – 0.31% 92
2018
Q2
$12.2M Hold
323,800
– – 0.47% 73
2018
Q1
$10.6M Hold
323,800
– – 0.45% 76
2017
Q4
$15.8M Hold
323,800
– – 0.72% 49
2017
Q3
$17.5M Buy
323,800
+184,100
+132% +$10.8M 0.81% 46
2017
Q2
$7.85M Buy
+139,700
New +$5.6M 0.4% 77
2016
Q3
– Sell
-175,000
Closed -$4.13M – 145
2016
Q2
$4.13M Hold
175,000
– – 0.31% 90
2016
Q1
$3.57M Buy
175,000
+10,000
+6% +$317K 0.3% 94
2015
Q4
$8.49M Buy
+165,000
New +$8M 0.64% 56

Rock Springs Capital Management's PTLA Position: Q3 2020 in Review

Rock Springs Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 2,306,196 shares — an estimated $41.5M sold.

Rock Springs Capital Management first reported a position in PTLA in Q4 2015 and held it in 16 quarters. The position peaked at $41.5M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Rock Springs Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Rock Springs Capital Management sold 2,306,196 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $41.5M.
  • Rock Springs Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 16 quarters.
  • Rock Springs Capital Management's Portola Pharmaceuticals, Inc. position peaked at $41.5M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.